360° Micropulse laser trabeculoplasty versus medical therapy in open-angle glaucoma: a randomized trial of efficacy, safety, and anterior segment morphological changes

Objective To evaluate the efficacy, safety, quality of life improvement, and morphological effects on the trabecular meshwork-Schlemm's canal outflow pathway of 360° MicroPulse Laser Trabeculoplasty (MLT) compared with guideline-escalated medical therapy in patients with open-angle glaucoma (OAG). Methods This prospective, randomized, parallel-group trial enrolled 90 patients with diverse OAG subtypes between February and April 2026. Participants were randomly assigned (1:1) to receive either 360° MLT (577 nm, 1000 mW, 15% duty cycle) or stepped medical therapy for 6 months. Primary outcomes included intraocular pressure (IOP) reduction, corneal endothelial cell density, and anterior segment optical coherence tomography (AS-OCT) quantification of Schlemm's canal diameter at baseline and month 3. Secondary outcomes comprised medication burden, Glaucoma Quality of Life-15 (GQL-15) scores, and adverse events. Results At 6 months, MLT achieved superior IOP reduction compared with medication (30.6% vs 21.8%; between-group difference 2.2 mmHg [95% CI: 1.1–3.3], P = 0.003). At month 3, AS-OCT demonstrated significant Schlemm's canal dilation with MLT (+37.2 μm, P < 0.001) but not medication. Corneal endothelium remained stable in both groups. MLT reduced medication burden by 61.1% (37.8% medication-free) versus no change with medication. GQL-15 scores improved more with MLT (5.8 vs. 1.1 points, P < 0.001). MLT had no serious adverse events; medication-related adverse events requiring intervention occurred only in the medication group (26.7% vs. 0%). Conclusions 360° MLT provides superior IOP control, reduced medication burden, and improved quality of life compared with medical therapy, and was associated with dilation of Schlemm's canal—a morphological change consistent with enhanced conventional aqueous outflow. These findings support MLT as an effective, medication-sparing early intervention for open-angle glaucoma. Clinical Trial Registration https://www.chictr.org.cn/showproj.html?proj=293191 , Number: ChiCTR2600117484; Registration Date: 20260126

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-16
DOI
https://doi.org/10.3389/fmed.2026.1985905
Primary Topic
Glaucoma and retinal disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

360° Micropulse laser trabeculoplasty versus medical therapy in open-angle glaucoma: a randomized trial of efficacy, safety, and anterior segment morphological changes

Na He, Jing Bao, Jialing He, Peiling Xie et al.
1 links
Frontiers in Medicine
Glaucoma and retinal disorders
article

360° Micropulse laser trabeculoplasty versus medical therapy in open-angle glaucoma: a randomized trial of efficacy, safety, and anterior segment morphological changes

Na He, Jing Bao, Jialing He, Peiling Xie, Xiaochun Li
article en

Abstract

Objective To evaluate the efficacy, safety, quality of life improvement, and morphological effects on the trabecular meshwork-Schlemm's canal outflow pathway of 360° MicroPulse Laser Trabeculoplasty (MLT) compared with guideline-escalated medical therapy in patients with open-angle glaucoma (OAG). Methods This prospective, randomized, parallel-group trial enrolled 90 patients with diverse OAG subtypes between February and April 2026. Participants were randomly assigned (1:1) to receive either 360° MLT (577 nm, 1000 mW, 15% duty cycle) or stepped medical therapy for 6 months. Primary outcomes included intraocular pressure (IOP) reduction, corneal endothelial cell density, and anterior segment optical coherence tomography (AS-OCT) quantification of Schlemm's canal diameter at baseline and month 3. Secondary outcomes comprised medication burden, Glaucoma Quality of Life-15 (GQL-15) scores, and adverse events. Results At 6 months, MLT achieved superior IOP reduction compared with medication (30.6% vs 21.8%; between-group difference 2.2 mmHg [95% CI: 1.1–3.3], P = 0.003). At month 3, AS-OCT demonstrated significant Schlemm's canal dilation with MLT (+37.2 μm, P < 0.001) but not medication. Corneal endothelium remained stable in both groups. MLT reduced medication burden by 61.1% (37.8% medication-free) versus no change with medication. GQL-15 scores improved more with MLT (5.8 vs. 1.1 points, P < 0.001). MLT had no serious adverse events; medication-related adverse events requiring intervention occurred only in the medication group (26.7% vs. 0%). Conclusions 360° MLT provides superior IOP control, reduced medication burden, and improved quality of life compared with medical therapy, and was associated with dilation of Schlemm's canal—a morphological change consistent with enhanced conventional aqueous outflow. These findings support MLT as an effective, medication-sparing early intervention for open-angle glaucoma. Clinical Trial Registration https://www.chictr.org.cn/showproj.html?proj=293191 , Number: ChiCTR2600117484; Registration Date: 20260126

Frontiers in MedicineVol. 13
Jinhua Central Hospital (CN), Zhejiang University (CN)
Good health and well-being
Glaucoma and retinal disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon